Evidence map›Paper›PMID 12388723›Full record

ArticleJournal of virology2002

Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Thorsten U Vogel, Thomas C Friedrich, David H O'Connor, William Rehrauer, Elizabeth J Dodds, Heather Hickman, William Hildebrand, John Sidney, Alessandro Sette, Austin Hughes and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Rhesus Cytomegalovirus-Specific CD8Frontiers in immunology · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Thorsten U VogelWisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin 53715, USA.
Thomas C Friedrich
David H O'Connor
William Rehrauer
Elizabeth J Dodds
Heather Hickman
William Hildebrand
John Sidney
Alessandro Sette
Austin Hughes
Helen Horton
Kathy Vielhuber
Richard Rudersdorf
Ivna P De Souza
Matthew R Reynolds
Todd M Allen
Nancy Wilson
David I Watkins
Autoimmune Technologies (United States) · USUniversity of Oklahoma Health Sciences Center · USUniversity of Wisconsin–Madison · USUniversity of South Carolina · USUW Health University Hospital · US

Funding

ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI CADWALLADER, MARTIN · 1985 to 2011
$106.7M
Molecular Basis of Immunity - Kirschtein-NRSAT32AI007633 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CUNNINGHAM, MADELEINE W. · 2001 to 2022
$4.0M
CTL-BASED VACCINES FOR THE AIDS VIRUSR01AI046366 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI WATKINS, DAVID I · 1999 to 2003
$1.7M
QUANTITATION OF T CELL RESPONSES TO VACCINATIONR21AI045461 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI WATKINS, DAVID I · 1999 to 2000
$273k
NCRR NIH HHS P51 RR000167NCRR NIH HHS RR00167NCRR NIH HHS RR1537NIAID NIH HHS AI45461NIAID NIH HHS AI46366NIAID NIH HHS R01 AI046366NIAID NIH HHS T32 AI007633
6 · The paper itself

Abstract

It is now accepted that an effective vaccine against AIDS must include effective cytotoxic-T-lymphocyte (CTL) responses. The simian immunodeficiency virus (SIV)-infected rhesus macaque is the best available animal model for AIDS, but analysis of macaque CTL responses has hitherto focused mainly on epitopes bound by a single major histocompatibility complex (MHC) class I molecule, Mamu-A*01. The availability of Mamu-A*01-positive macaques for vaccine studies is therefore severely limited. Furthermore, it is becoming clear that different CTL responses are able to control immunodeficiency virus replication with varying success, making it a priority to identify and analyze CTL responses restricted by common MHC class I molecules other than Mamu-A*01. Here we describe two novel epitopes derived from SIV, one from Gag (Gag(71-79) GY9), and one from the Nef protein (Nef(159-167) YY9). Both epitopes are bound by the common macaque MHC class I molecule, Mamu-A*02. The sequences of these two eptiopes are consistent with the molecule's peptide-binding motif, which we have defined by elution of natural ligands from Mamu-A*02. Strikingly, we found evidence for the selection of escape variant viruses by CTL specific for Nef(159-167) YY9 in 6 of 6 Mamu-A*02-positive animals. In contrast, viral sequences encoding the Gag(71-79) GY9 epitope remained intact in each animal. This situation is reminiscent of Mamu-A*01-restricted CTL that recognize Tat(28-35) SL8, which reproducibly selects for escape variants during acute infection, and Gag(181-189) CM9, which does not. Differential selection by CTL may therefore be a paradigm of immunodeficiency virus infection.

Indexed as

Amino Acid SequenceAnimalsCell LineEpitope MappingEpitopes, T-LymphocyteEvolution, MolecularGene Products, gagGene Products, nefHistocompatibility Antigens Class IImmunodominant EpitopesMacaca mulattaMolecular Sequence DataSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusT-Lymphocytes, CytotoxicEpitopes, T-LymphocyteGene Products, gagGene Products, nefHistocompatibility Antigens Class IImmunodominant EpitopesMamu-A 02 antigen

Identifiers

PMID12388723
PMCPMC136802
OpenAlexW2124051961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.